Fermenta Biotech Performance
- Today's Low
- ₹285
- Today's High
- ₹312
- 52 Week Low
- ₹249
- 52 Week High
- ₹330
- Open Price₹306
- Previous Close₹304
- Volume49,328
- 50 DMA₹310.63
- 100 DMA₹315.97
- 200 DMA₹316.49
Fermenta Biotech Chart
Investment Returns
- Over 1 Month -8.92%
- Over 3 Month -14.55%
- Over 6 Month + 5.83%
- Over 1 Year -1.41%
Smart Investing Starts Here Start SIP with Fermenta Biotech for Steady Growth!
Fermenta Biotech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 11.8
- PEG Ratio
- -2.1
- Market Cap Cr
- 855
- P/B Ratio
- 2.1
- Average True Range
- 11.86
- EPS
- 30.06
- Dividend Yield
- 0.9
- MACD Signal
- -6.92
- RSI
- 41.03
- MFI
- 40.79
Latest Stock News Updates
Over the past five trading sessions, select smallcap stocks posted gains of up to 27%. Fermenta Biotech led with a 26% rise, followed by Stallion India Fluorochemicals and Rolex Rings. Sectors such as niche pharma, specialty chemicals, auto components, media, IT, and infrastructure witnessed renewed investor interest. The rally highlights heightened volatility, speculative activity, and rapid price discovery in smaller companies.
- Economic Times
- 5 months 1 week ago
Pharmaceuticals company Fermenta Biotech announced Q1FY26 results Q1FY26 Consolidated Revenue Rs 145 crore, up 79% YoY. Consolidated EBITDA for Q1FY26 Rs 37 crore, up 922% YoY. PAT: Rs 21.6 crore vs Rs 5.9 crore loss during Q1FY25. EPS: Rs 7.49 for Q1FY26. Prashant Nagre, Managing Director, said: “Continuing our financial and operational turnaround of FY25, we delivered exceptional performance this quarter with strong YoY growth in revenue and EBITDA, driven by robust volume and price expansion across our human and animal nutrition segments. Fermenta’s strategic initiatives, including partnerships with NIFTEM-T and GAIN, strengthen our market position for sustained future growth." Result PDF
- Trendlyne
- 9 months 2 weeks ago
Pharmaceuticals company Fermenta Biotech announced Q3FY25 results Revenue: Rs 156.5 crore (up 58 % YoY, up 65 % QoQ). EBITDA: Rs 55.5 crore (up 101 % YoY, up 156 % QoQ). Profit after tax: Rs 37.9 crore (up 279 % YoY, up 241 % QoQ). EPS: Rs 12.71 (up 273 % YoY, up 222 % QoQ). Prashant Nagre, Managing Director, said: “The significant YoY and QoQ increase in revenue and EBITDA was on the back of volume and price growth in both Human and Animal Nutrition. Increased market demand in the Human Nutrition segment in key markets such as North America and Europe; approvals with key global accounts in animal nutrition also led to increased volumes in this segment.” Result PDF
- Trendlyne
- 1 year 3 months ago
Fermenta Biotech Financials
Fermenta Biotech Technicals
EMA & SMA
- Bearish Moving Average 0
- Bullish Moving Average 0
- 20 Day
- ₹300.55
- 50 Day
- ₹310.63
- 100 Day
- ₹315.97
- 200 Day
- ₹316.49
Resistance and Support
- R3 322.13
- R2 315.57
- R1 303.08
- S1 284.03
- S2 277.47
- S3 264.98
Fermenta Biotech Corporate Actions - Bonus, Splits, Dividends
About Fermenta Biotech
- NSE Symbol
- FERMENTA
- BSE Symbol
- 506414
- Managing Director
- Mr. Prashant Nagre
- ISIN
- INE225B01021
Similar Stocks to Fermenta Biotech
Popular Stocks
Fermenta Biotech FAQs
Fermenta Biotech share price is ₹290 As on 26 May, 2026 | 21:16
The Market Cap of Fermenta Biotech is ₹855.3 Cr As on 26 May, 2026 | 21:16
The P/E ratio of Fermenta Biotech is 11.8 As on 26 May, 2026 | 21:16
The PB ratio of Fermenta Biotech is 2.1 As on 26 May, 2026 | 21:16
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.